Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
- Plozasiran reduced triglycerides by 80% from baseline and reduced the risk…
- Plozasiran reduced triglycerides by 80% from baseline and reduced the risk…
